Drug profile · INN
oxaliplatin
OXALIPLATIN ACCORD
oxaliplatin (OXALIPLATIN ACCORD) is a dna inhibitor. Associated with BAXTER HEALTHCARE PTY LTD. Route of administration: injection. Current US regulatory status: approved.
Drug details — oxaliplatin
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 129
- Data quality
- 0.89
Quick answer
oxaliplatin (OXALIPLATIN ACCORD) is a dna inhibitor. Associated with BAXTER HEALTHCARE PTY LTD. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
DNA inhibitor
Primary target: DNA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is oxaliplatin?
oxaliplatin (OXALIPLATIN ACCORD) is a dna inhibitor. Associated with BAXTER HEALTHCARE PTY LTD. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for oxaliplatin?
OXALIPLATIN ACCORD is a marketed brand name for oxaliplatin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of oxaliplatin?
oxaliplatin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.